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Background: Elevation of cardiac markers in patients with renal dysfunction has not been fully assessed
reducing the diagnostic usefulness of these biomarkers.
Objective: To examine the effects of renal function and amedical record of cardiovascular disease on levels of
cardiac biomarkers.
Methods: Serum samples were collected from 489 patients referred for GFR measurement using Cr51-EDTA
or iohexol plasma clearance (measured GFR). The cardiac biomarkers Troponin T (hs-cTnT), Troponin I (hsTnI),
N-Terminal pro-Brain Natriuretic Peptide (NTproBNP), Copeptin, Human Fatty Acid-Binding Protein (hFABP),
as well as the kidney function biomarkers creatinine and cystatin C, were measured. Regression was used to
analyse the relationship between biomarker levels and the glomerular ﬁltration rate (GFR) between 15 and
90 mL/min/1.73 m2.
Results:Comparedwith normal kidney function, the estimated increases in the studied cardiac biomarkers at
a GFR of 15 mL/min/1.73 m2 varied from 2-fold to 15-fold but were not very different between patients with or
without a medical record of cardiovascular disease and were most prominent for cardiac biomarkers with low
molecular weight. hs-cTnT levels correlated more strongly to measured GFR and increased more at low GFR
compared to hs-cTnI. For hFABP and NTproBNP increases at low kidney function were more correctly predicted
by a local Cystatin C-based eGFR formula compared with creatinine-based eGFR (using the MDRD or CKD-EPI
equations).
Conclusion: The extent of the elevation of cardiac markers at low renal function is highly variable. For hFABP
and NTproBNP Cystatin C-based eGFR provides better predictions of the extent of elevation compared to the
MDRD or CKD-EPI equations.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The diagnosis of cardiac disease, such as heart failure and myo-
cardial infarction, often involves cardiac damage biomarkers such
as cardiac troponin T (cTnT), cardiac troponin I (cTnI) [1,2], and
human fatty acid-binding protein (hFABP) [3,4]. In addition, hor-
mones secreted in response to cardiac stress, such as brain natriuret-
ic peptide (BNP) and anti-diuretic hormone (ADH), also provideistry and TransfusionMedicine,
rsity of Gothenburg, SE-41345
ammarsten).
of Clinical Chemists. Published bydiagnostic and prognostic information in heart failure andmyocardi-
al infarction. The production of BNP and ADH is generally estimated
on the basis of the circulating levels of N-Terminal pro-Brain Natri-
uretic Peptide (NTproBNP) [5,6] and Copeptin [7–11], apparently in-
active peptides that are secreted in equimolar amounts together
with the active stress hormones.
Cardiovascular disease is common among patients with renal insuf-
ﬁciency [12]. It is well known that cardiac biomarkers are often in-
creased in patients with impaired renal function due to decreased
clearance, as a part of the cardio-renal syndrome, uraemic cardiotoxins
[12] or a combination [13,14] of these factors. However, the extent of el-
evation expected at a given glomerular ﬁltration rate (GFR) is not well
examined for most cardiac biomarkers. This impairs the diagnosticElsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
303C. Bjurman et al. / Clinical Biochemistry 48 (2015) 302–307precision in patientswith poor renal function and suspected cardiac dis-
ease, especially in the acute setting [15].
Renal function is often not measured directly via Cr51-EDTA or
iohexol plasma clearance (measured GFR) [16], but estimated on the
basis of the levels of endogenous ﬁltration biomarkers, such as creati-
nine or cystatin C. Creatinine and Cystatin C are produced at a
relatively constant rate and are, for the most part, cleared via renal
ﬁltration. Steady-state concentrations of creatinine and cystatin C there-
fore reﬂect renal ﬁltration rate and can be used to estimate GFR (eGFR)
[17]. It is still debated if eGFR calculated using creatinine or cystatin C
levels more closely predict measured GFR and GFR-related outcomes
[18,19].
We have examined the extent of elevation of common cardiac bio-
markers in stable patients with a known GFR. We have also evaluated
whether the eGFR, calculated from a local cystatin C-based equation,
and creatinine, calculated using the MDRD or CKD-EPI equations, differ
in their ability to predict elevations of cardiac biomarkers in patients
with poor kidney function.
Methods
Study cohort
This study included 489 patients prospectively referred formeasure-
ment of Cr51-EDTA or iohexol clearance [7] at the Department of Clini-
cal Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden,
during 2009–2011, who agreed to participate in the study. Medical re-
cords were reviewed, especially if the patients had high levels of cTnT
and other cardiac biomarkers. Based on this review, 29 patients were
excluded due to serious illness that was judged as the major reason
for the biomarker elevation by a physician. The reasons for exclusion
are listed in Supplemental Fig. 1. The remaining 460 patients were
divided based on the presence (n = 223) or absence (n = 237) of car-
diovascular disease, as determined by the presence or absence of an
ICD10 diagnosis code beginning with the letter I, such as atrial ﬁbrilla-
tion (I489, I489A, I489B), heart failure (I500, I501, I509), CIHD, old
myocardial infarction and angina (I259, I258, I228, I229, I252, I209).
Ten patients lacked available diagnostic codes and were not included
in analyses of patients with and without cardiovascular disease and
were thus only present in the analysis of all patients. The study protocol
was approved by the Ethical Committee at the University of Gothen-
burg. Written informed consent was obtained from all patients and
the study protocol conforms to the ethical guidelines of the 1975 Decla-
ration of Helsinki.
Laboratory analyses
One or two-point iohexol plasma clearance or Cr51-EDTA plasma
clearance was used to measure GFR (measured GFR). The relative per-
formance of these routinemethods has been evaluated by simultaneous
injection of Cr51-EDTA and iohexol in the same patients and the two
methods were found to generate similar results [16]. Blood sampling
was carried out at the same time as GFR measurement. Serum was
stored at−70 °C before analysis. All blood samples were analysed at
the Clinical Chemistry Laboratory at Sahlgrenska University Hospital.
The coefﬁcient of variation (CV) calculated based on 12 repeated analy-
sis on 3 consecutive days on the Roche's COBAS methods were; creati-
nine (CV 2.1%), Cystatin C (CV 1.7%), NTproBNP (CV 4.9%), and hs-TnT
(3.3%). The coefﬁcient of variation (CV) calculated based on 12 repeated
analysis on 3 consecutive days were; hFABP (CV 1.3%, Randox),
Copeptin (CV 4.1%, Brahms) and hs-TnI (CV 6.9%, Abbot). Further infor-
mation on the methods are summarised in Supplemental Table 1. The
estimated Glomerular Filtration Rate (eGFR) was calculated using de-
mographics and creatinine concentrations according to the Modiﬁca-
tion of Diet in Renal Disease Study (MDRD) formula [20] or CKD-EPI
[21]. The eGFR based on CysC was calculated using a locally generatedequation (GFR (mL/min/1.73 m2) = (85.47/CysC (mg/L)) − 9.64).
This equation was was based on linear regression from Cystatin C con-
centrations and measured GFR using Cr51-EDTA or iohexol plasma
clearance. The data andmore details are included in supplementary ﬁg-
ure 2. The CVs were calculated. The slope and the performance of this
equation are summarised in Supplemental Figure 2.
Statistical analysis
Univariate comparisons between GFR groups were calculated using
independent samples median tests (in Table 1 and Supplemental
Table 2–3). Dichotomous variables were analysed using exact tests
with Monte Carlo methods (in Table 1 and Supplemental Table 2–3).
Functions to predict fold increases were identiﬁed using regression
analyses on logarithmised levels of biomarkers used as dependent var-
iables and logarithmised measured GFR values used as independent
variables on patients with a measured GFR of ≥15 mL/min/1.73 m2.
The resulting mean functions (Log(Y) = a + b Log(X)) were used to
calculate the estimated increase in each cardiac biomarker at a mea-
sured GFR of 60, 30 and 15 mL/min/1.73 m2, using cardiac biomarker
levels (estimated from the mean functions) at a measured GFR of
90 mL/min/1.73 m2 as the reference. These regressions were also per-
formed using eGFR from creatinine (calculated from the MDRD or
CKD-EPI equations) and cystatin C (calculated from the local cystatin
C equation) as the independent variable for each cardiac biomarker.
To compare fold increases between different biomarkers Friedman
tests and related samples Wilcoxon rank tests were used on
actual biomarker levels among patients with GFR between ≥15 and
b30mL/min/1.73m2 after division by themedian levels amongpatients
with ≥GFR 90 mL/min/1.73 m2. Fold increases between patients with
and without I-diagnoses were compared using independent-samples
median tests on the above described ratios. The ability of MDRD eGFR
and CKD EPI eGFR to predict biomarker levels compared to cysC eGFR
was analysed with related samples Wilcoxon rank tests. The absolute
differences between actual biomarker levels and estimates from the re-
spectivemean functions (Log(Y)= a+b Log(X)) were then compared.
Statistical analyses and calculationswere performed using the SPSS ver-
sion 20, MedCalc 13 andMicrosoft Excel 2010. All tests were two-tailed,
and p values b 0.05 were regarded as signiﬁcant.
Results
Study population
The 460 patients admitted for measurement of GFR (by either Cr51-
EDTA or iohexol clearance) and included in the study (Supplemental
Fig. 1) had a median age of 58 (IQR 45–65) years and 56% were males.
Biomarker levels and the percentages with CVD and diabetes in the
medical record were higher among patients with a low GFR (Table 1).
Therefore, patients with (n = 223) and without (n = 227) CVD in the
medical record were also analysed separately (Supplemental Table 2
and 3). All studied cardiac biomarkers increased in a GFR-dependent
manner in both cohorts but were higher in the CVD cohort at lowmea-
sured GFRs (p b 0.05 for all studied biomarkers at GFR ≥ 15 and b60).
The frequency of different CVD diagnoses, such as heart failure, was
the same over the GFR quartiles in the CVD cohort (Supplemental
Table 2).
Regression analysis of cardiac biomarker levels at different measured GFRs
Mean functions from regression analyses of cardiac biomarker levels
and measured GFRs (Fig. 1) were used to calculate the fold increase in
each biomarker at measured GFRs of 15, 30, and 60 mL/min/1.73 m2,
compared with the levels in patients with normal kidney function
(90 mL/min/1.73 m2) (Table 2). The regression analysis only included
data from patients without renal failure, (GFR ≥ 15 mL/min/1.73 m2),
Table 1
Baseline characteristics for all patients included in the study.
Measured GFR GFR b 15a GFR ≥ 15 and b30a GFR ≥ 30 and b60a GFR ≥ 60 and b90a GFR N=90a P value
n = 460 30 54 146 148 80
GFR (mL/min/1.73 m2)
Measured GFR 12 (10–13) 23 (17–26) 44 (36–51) 73 (65–81) 99 (95–105) b0.001
CysC eGFR 10 (8–13) 21 (17–24) 39 (31–46) 62 (53–68) 79 (71–93) b0.001
MDRD eGFR 14 (11–17) 28 (23–34) 48 (40–60) 77 (68–94) 99 (87–116) b0.001
CKD EPI eGFR 12 (8.8–17) 26 (21–36) 50 (36–67) 87 (63–101) 102 (80–115) b0.001
Renal function markers
CysC (mg/L) 3.3 (2.9–3.6) 2.3 (2.1–2.6) 1.5 (1.3–1.8) 1.0 (0.96–1.2) 0.86 (0.75–0.93) b0.001
Creatinine (mmol/L) 350 (309–459) 193 (155–238) 118 (97–147) 79 (66–94) 67 (55–76) b0.001
Cardiac biomarkers
hs-cTnT (ng/L) 41 (25–59) 21 (12–37) 15 (10–21) 9.4 (7.5–14) 7.1 (5.8–10) b0.001
hs-cTnI (ng/L) 16 (11–27) 11 (7,5–19) 7.6 (5.1–11) 5.0 (4.1–6.8) 4.6 (3.3–7.1) b0.001
NTproBNP (ng/L) 759 (352–2686) 789 (253–1790) 185 (87–471) 121 (51–271) 48 (27–93) b0.001
Copeptin (pmol/L) 77 (56–89) 35 (24–47) 17 (10–27) 9 (5–14) 6 (4–9) b0.001
hFABP (mg/L) 20 (16–23) 10 (8,2–14) 6.2 (4.8–8.2) 3.5 (2.9–4.4) 2.6 (2.1–3.3) b0.001
Clinical variables
Age 62 (53–70) 61 (53–69) 61 (50–67) 54 (42–64) 47 (35–57) b0.001
Sex (males) 73% 61% 58% 53% 55% 0.30
Comorbidity
I diagnosis 90% 70% 60% 38% 23% b0.001
IHD 21% 15% 8% 6% 1% 0.004
AF 14% 11% 6% 2% 4% 0.03
Heart failure 17% 8% 8% 3% 1% 0.009
Hypertension 66% 43% 42% 21% 10% b0.001
Diabetes 45% 21% 19% 8% 4% b0.001
Stroke 0% 4% 2% 2% 1% 0.82
COPD 0% 2% 3% 2% 1% 0.75
AF: Atrial ﬁbrillation; COPD: chronic obstructive pulmonary disease; CysC: Cystatin C; eGFR: estimated glomerular ﬁltration rate (mL/min/1.73 m2); GFR: glomerular ﬁltration
rate (mL/min/1.73 m2); HFabp: Human Fatty Acid Binding Protein; hsTnI: high-sensitivity Troponin I; hs-cTnT: high-sensitivity cardiac Troponin T; I-diagnosis: ICD-10 code
beginning with I; IHD: Ischemic heart disease; MDRD: Modiﬁcation of Diet in Renal Disease Study; NTproBNP: N-Terminal pro Brain Natriuretic Peptide.
a Data is presented as medians (interquartile ranges) or proportions.
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ical record. Levels of all studied biomarkers were signiﬁcantly higher at
low GFR (Table 1 and 2). The association between GFR and biomarker
levels was strong for hFABP (R2 0.57 CI 0.51–0.63) but the association
was poor (R2 b 0 .35) for cTnI, cTnT and NTproBNP (Supplemental
Table 4). In the entire study cohort and among patients with CVD in
the medical record, hs-cTnT levels had a stronger association to mea-
sured GFR compared to hs-cTnI with no overlap in the coefﬁcient of de-
termination (R2) conﬁdence interval (Supplemental Table 4). The
increase in studied cardiac biomarkers at a GFR of 15 mL/min/1.73 m2,
compared with normal kidney function, varied from 2.9-fold to 15-
fold and was not signiﬁcantly different for patients with or without
CVD in the medical record except for hs-cTnT (p = 0.007) (Table 2).
The regression-estimated increase of hs-cTnT was signiﬁcantly higher
at low measured GFR compared to hs-cTnI (Table 2).
Regression analysis of cardiac biomarker elevation using creatinine and
cystatin C-based eGFR
Regression analyses of cardiac biomarker levels and cystatin C-based
eGFR (using the local cystatin C equation) and creatinine based eGFR
(using the MDRD or CKD-EPI equations) were compared (Table 3).
Projected increases using cystatin C-based eGFR for all ﬁve studied car-
diac biomarkerswere signiﬁcantly closer to the actual values in each pa-
tient compared to predictions using MDRD and for hFABP and
NTproBNP using CKD-EPI (supplemental table 4). Regressions using
the local cystatin C equation resulted in signiﬁcantly higher coefﬁcient
of determination (R2) compared with the MDRD equation for hs-cTnT
and hFABP (Supplemental Table 4).
Discussion
In this study we have attempted to estimate GFR-dependent eleva-
tions of ﬁve commonly used cardiac biomarkers (hs-cTnI, hs-cTnT, NT-proBNP, hFABP and copeptin) in stable patients with varying kidney
function. These types of studies are problematic, as the increase in the
levels of cardiac biomarkers is expected to be a combination of de-
creased clearance, increased production due to the cardio-renal syn-
drome and the fact that cardiac disease is more common among
patients with poor kidney function. With these limitations in mind,
some conclusions may still be drawn from our study.
Firstly, theGFR-dependent levels of cTnT andNTproBNP in our study
were in agreement with those in previous studies [22–25]. Similar to
previous studies, we ﬁnd that the association between measured GFR
and NTproBNP and cTnT was poor, with an R2 of less than 0.35, in con-
trast with the strong association betweenmeasured GFR and the classi-
cal kidney function biomarkers creatinine and cystatin C. Similar to a
previous study we found that the levels of cTnI were less affected by
GFR compared with the levels of cTnT [26].
Secondly, cardiac biomarkers with a molecular weight below
25 kDa, and therefore expected to have a relatively free passage through
the glomerular ﬁltration membrane, such as NTproBNP, copeptin and
hFABP, showed a more pronounced increase at low measured GFRs
compared with cTnT and cTnI (p b 0.05 by Friedman mean ranks test),
which have molecular weights above 25 kDa. Thus, our study indicates
that renal function is a less important clearance mechanism for cTnT
and cTnI compared with NTproBNP, hFABP and copeptin.
It is, however, important to note that the dominant clearance mech-
anism for any of the studied biomarkers is not fully known. For instance,
the renal extraction index, the difference in the NTproBNP concentra-
tion in blood from the renal artery and the renal vein is close to its max-
imum value of 0.2 in patients [27]. However, although NTproBNP is
cleared by the kidneys [28], several studies indicate that NTproBNP ele-
vations often observed in patients with poor kidney function are likely a
reﬂection of increased production from the heart [29]. For instance, the
levels of NTproBNP have a preserved ability to predict the heart failure
diagnosis and prognosis in patients with poor kidney function without
adjustment for GFR [30,31]. Therefore, although NTproBNP is cleared
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Fig. 1.Dot-plot presentation of the data used in the regression analyses usingmeasured GFR (either by Cr51-EDTA or iohexol clearance). The dotted lines indicate renal failure (measured
GFR of 15 mL/min/1.73 m2).
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Table 2
Fold elevationa of cardiac biomarkers at different levels of GFR compared with normal kidney function.
All With CVD
diagnosis
No CVD diagnosis
Measured GFR (mL/min/1.73 m2) 90 60 30 15 90 60 30 15 90 60 30 15
hs-cTnT 1 1.3 2.2 3.6bc 1 1.3 2.2 3.7d 1 1.2 1.7 2.4d
hs-cTnI 1 1.3 1.9 2.9bc 1 1.2 1.6 2.2 1 1.2 1.7 2.3
NTproBNP 1 1.9 5.3 15.2b 1 1.7 4.1 9.9 1 1.8 4.7 12.4
Copeptin 1 1.5 3 6.1b 1 1.5 3 5.9 1 1.4 2.6 4.9
hFABP 1 1.4 2.7 5.1b 1 1.4 2.7 5.1 1 1.3 1.9 2.8
CysC: Cystatin C; eGFR: estimated glomerular ﬁltration rate; GFR: glomerular ﬁltration rate; HFabp: Human Fatty Acid-Binding Protein; hs-cTnT: high-sensitivity cardiac Troponin T;
MDRD: Modiﬁcation of Diet in Renal Disease Study; hsTnI: high-sensitivity Troponin I; NTproBNP: N-Terminal pro-Brain Natriuretic Peptide.
a Based on regression analyses using biomarker levels and measured GFR.
b Difference in fold elevation: hs-cTnI b hs-cTnT b hFABP b Copeptin b NTproBNP by Friedman mean ranks test (p b 0.001).
c Fold elevation: hs-cTnI b hs-cTnT byWilcoxon Signed Rank Test (p b 0.001).
d Higher elevation of hs-cTnT in patients with CVD compared to patients without CVD by independent samples median tests (p = 0.007).
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dominates for NTproBNP. An example of this is myoglobin that has a
free passage through the glomerular membrane (18 kDa) but still
have the same half-life in patients with or without impaired kidney
function [32–34], suggesting a major role for extra-renal clearance.
The exact mechanisms of the extra-renal clearance of these proteins
and peptides are unknown but likely involve proteolytic degradation
and scavenger receptor-mediated uptake in the liver and macrophages
[35].
Thirdly, the levels of the ﬁve cardiac biomarkers were generally
higher in patients with CVD in their medical records. This was likely a
result of the increased production in patients with CVD. For instance,
left ventricular mass and hypertension are GFR-independent predictors
of the cTnT levels in patients with chronic kidney disease, probably due
to increased cTnT release from the heart in these conditions [23]. In ad-
dition, the prognostic impact of elevated NTproBNP, cTnT, MRproANP,
MRproADM and copeptin in patients with heart failure is independent
of renal function, indicating that increased production rather than de-
creased renal clearance is the dominating reason for the observed eleva-
tion at low GFR [31].
Because the levels of the studied cardiac biomarkers were higher
among patients in the CVD cohort, also at normal kidney function, the
relative GFR-dependent increase in cardiac biomarkers was similar in
cohorts with or without CVD in themedical record. Therefore, although
the absolute levels of the studied cardiac biomarkers were higher in pa-
tients with CVD in the medical record, the relative GFR-dependent in-
crease was similar in the cohorts with and without CVD in the medical
record. The fact that the relative frequency of different cardiovascular
diseases was the same at different GFR levels in the CVD cohort likely
contributed to this effect.
As discussed above, it is unclear in our study, as inmost similar stud-
ies [22,23,31], to which extent the increased production or decreased
kidney clearance contributed to the increases in cardiac biomarker
levels observed among patients with a low GFR. A possible exceptionTable 3
Comparison of the ability ofMDRD eGFR or CKD EPI eGFR versus CysC eGFR to predict bio-
marker levels.
Biomarker CysC eGFR versus MDRD eGFR CysC eGFR versus CKD EPI eGFR
hs-cTnT p b 0.001a p = 0.22
hs-cTnI p b 0.001a p = 0.41
NTproBNP p b 0.001a p b 0.001a
Copeptin p b 0.001acih p = 0.61
Hfabp p b 0.001a p b 0.001a
CysC: Cystatin C; eGFR: estimated glomerular ﬁltration rate; HFabp: Human Fatty Acid-
Binding Protein; hs-cTnT: high-sensitivity cardiac Troponin T; MDRD: Modiﬁcation of
Diet in Renal Disease Study; hsTnI: high-sensitivity Troponin I; NTproBNP: N-Terminal
pro-Brain Natriuretic Peptide.
a Predictions by CysC signiﬁcantly better with related samples Wilcoxon rank tests.was the level of hFABP, which did not differ much between patients
with or without CVD and showed the highest association to measured
GFR with a R2 that overlapped with the conﬁdence interval for the R2
for creatinine. This indicates that decreased renal clearance contributed
to the GFR-dependent elevations of hFABP.
Lastly, our study indicates that using a locally generated formula for
cystatin C-based eGFR result in better predictions of GFR-dependent in-
creases, at least for hFABP and NTproBNP, compared with creatinine-
based predictions (Table 3). This could be due to the fact that cystatin
C-based eGFR often outperform creatinine as a method to estimate
GFR [36]. In line with this possibility, cystatin C levels are more strongly
correlated with cardiovascular disease and mortality than creatinine
levels in several studies [37–40].
However, although not signiﬁcant, we observed that the cystatin C-
based eGFR often correlated to a higher degree with our studied cardiac
biomarker levels than the measured GFR (Supplemental Table 2). It is
therefore possible that conditions that result in an increased production
of cardiac biomarkers, such as the cardio-renal syndrome, also increase
the cystatin C production. In line with this possibility, cystatin C was
shown to be a predictor of the prognosis in ischemic cardiovascular dis-
ease in patients with a normal GFR [41], and was a better predictor of
cardiovascular death compared with the measured GFR in patients
with chronic kidney disease [42].
A limitation of this study was that the cardiac function of the partic-
ipants was not systematically evaluated and only based on information
inmedical records. As a result, left ventricularmass that has been shown
to correlate with the cTnT and NTproBNP levels in patients with kidney
failure [23,24] was not systematically evaluated. Another problem was
that the study cohort was not composed of a speciﬁc patient group.
Potential strengths are the multitude of biomarkers measured simulta-
neously, allowing direct comparison of their associationwithGFR. In ad-
dition, and in contrast with many previous studies, GFR was measured
directly with Cr51-EDTA or iohexol in all patients.
In conclusion, this study provides estimates of the extent of eleva-
tion of several important cardiac biomarkers at low renal function
(Table 2) and indicates that estimates using cystatin C is better than es-
timates using creatinine at least for hFABP and NTproBNP (Table 3).Competing interests
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